Company Short-Term Debts: Fluidigm (LAB)

Public company logo of Standard BioTools Inc. (LAB)

The market price for Standard BioTools Inc. (LAB), whose operations are based on laboratory diagnostics, as confirmed by the chart on GURU.Markets, is 0.00. Standard BioTools Inc. (LAB) maintains a staff of key scientists and attracts specialized managers. However, global system sales are complicated by trade barriers and logistical disruptions in Asia. Demand for equipment depends on biotechnology investments, although the shift toward personalized medicine provides stability.

LAB Standard BioTools Inc Company Short-Term Debt (04/28/2023 - 10/28/2026)

Summary analytical data breakdowns for Standard BioTools Corp (LAB)

- price and consensus price forecast:
Price Chart Standard BioTools|LAB - Broker Consensus Forecast
- market capitalization data:
Market Capitalization Standard BioTools Inc.|LAB - Enterprise Value
- book capitalization data:
Net Assets per Single Share Standard BioTools|LAB - Company Book Value|Market Cap to Net Assets Ratio fluidigm.com|LAB - Company Assets
- debt and liquidity data:
Debt to Equity Standard BioTools Inc.|LAB - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital Standard BioTools Inc.|LAB - Company Total Debt Obligations|Debt to Book Capitalization Ratio Standard BioTools Inc.|LAB - Long-Term Debt Volume|Company Short-Term Debt Standard BioTools
Fundamental company valuation:Standard BioTools LAB
Product sample of Standard BioTools Corp

Conservative capital demands absolute transparency of the liability structure to assess a business's solvency. This indicator captures the volume of borrowed funds due within a year, evaluating the current debt load. For Standard BioTools Inc. (LAB), such funds support expansion in the mass cytometry segment, where high B2B customer loyalty guarantees a stable cash flow. Analyzing financial liabilities with a maturity of up to 12 months allows for liquidity tracking between SEC reports. An upward trend in this curve signals an intensification of asset turnover alongside an increase in credit risks.

Competitor analysis for Standard BioTools Inc.

Agilent (A) - Company Short-Term Debt|DGX - Company Short-Term Indebtedness|ILMN: Company Short-Term Debts|EXAS (Exact Sciences Inc.) - Company Short-Term Debts|Company Short-Term Debt Revvity, Inc.|Company Short-Term Debt bio-rad.com (BIO)|Anbio - Company Current Liabilities|Short-Term Debt SHC (Sotera Health Corp)|Company Short-Term Debt QDEL|Short-Term Debt Volume OPKO Health Corp. OPK|Company Short-Term Debts CDNA (CareDx, Inc.)|MRVI: Short-Term Debt Volume|Fulgent Genetics - Company Short-Term Debt|CTKB (Cytek Biosciences Inc) - Short-Term Debt Volume|OSUR: Company Short-Term Debt|Short-Term Debt Volume Exagen Diagnostics (XGN)|Company Current Liabilities MDxHealth SA|Amount of Current Liabilities luciddx.com (LUCD)|Company Short-Term Debts PRE (Prenetics)|Insight Molecular Diagnostics, Inc. - Company Short-Term Debts|Trinity Biotech Corp (TRIB) - Company Short-Term Debt|PRPH - Company Short-Term Indebtedness|Company Short-Term Debts Ainos, Inc.|codiagnostics.com (CODX) - Company Short-Term Indebtedness|HSCS (HeartSciences) - Company Short-Term Debts|Company Short-Term Debts BMRA|Cardio Diagnostics (CDIO) - Company Short-Term Debt|Company Short-Term Loans and Borrowings Virax Biolabs Corp (VRAX)|BJDX - Company Short-Term Debts|AWH - Company Short-Term Indebtedness|Company Current Liabilities Accelerate Diagnostics, Inc. (AXDX)|CNTG - Company Short-Term Loans and Borrowings|enzo.com (ENZ) - Company Short-Term Debts|Fresh2 Group (FRES) - Company Short-Term Debt|GENE: Company Short-Term Debts|Short-Term Debt Volume ME|Psychemedics Corporation - Company Short-Term Debt